Novartis publish series of MK2 inhibitors « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Novartis publish series of MK2 inhibitors

Posted on October 14, 2008 by crimsoncanary

Novartis have published a series of pyrrolo-pyrimidone MK2 Inhibitors

Filed under: Uncategorized | Tagged: kinase, MK2, Novartis, Preclinical, Research

« Kinaxo collaborate with Boehringer Ingelheim to study mode of action and target identification Pfizer have published a series of PYK2 inhibitors »